Oleocanthal Ameliorates Metabolic and Behavioral Phenotypes in a Mouse Model of Alzheimer's Disease

被引:4
作者
Yang, Euitaek [1 ]
Wang, Junwei [1 ]
Woodie, Lauren N. [2 ]
Greene, Michael W. [2 ]
Kaddoumi, Amal [1 ]
机构
[1] Auburn Univ, Harrison Coll Pharm, Dept Drug Discovery & Dev, 720 S Donahue Dr, Auburn, AL 36849 USA
[2] Auburn Univ, Coll Human Sci, Dept Nutr, Auburn, AL 36849 USA
来源
MOLECULES | 2023年 / 28卷 / 14期
关键词
Alzheimer's disease; blood-brain barrier; metabolic phenotype; sleep behavior; Promethion cages; oleocanthal; TRANSGENIC MICE; IN-VITRO; SLEEP QUALITY; CLEARANCE; TOXICITY; WEIGHT; LOAD; DIET;
D O I
10.3390/molecules28145592
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Aging is a major risk factor for Alzheimer's disease (AD). AD mouse models are frequently used to assess pathology, behavior, and memory in AD research. While the pathological characteristics of AD are well established, our understanding of the changes in the metabolic phenotypes with age and pathology is limited. In this work, we used the Promethion cage systems(& REG;) to monitor changes in physiological metabolic and behavioral parameters with age and pathology in wild-type and 5xFAD mouse models. Then, we assessed whether these parameters could be altered by treatment with oleocanthal, a phenolic compound with neuroprotective properties. Findings demonstrated metabolic parameters such as body weight, food and water intake, energy expenditure, dehydration, and respiratory exchange rate, and the behavioral parameters of sleep patterns and anxiety-like behavior are altered by age and pathology. However, the effect of pathology on these parameters was significantly greater than normal aging, which could be linked to amyloid-& beta; deposition and blood-brain barrier (BBB) disruption. In addition, and for the first time, our findings suggest an inverse correlation between sleep hours and BBB breakdown. Treatment with oleocanthal improved the assessed parameters and reduced anxiety-like behavior symptoms and sleep disturbances. In conclusion, aging and AD are associated with metabolism and behavior changes, with the changes being greater with the latter, which were rectified by oleocanthal. In addition, our findings suggest that monitoring changes in metabolic and behavioral phenotypes could provide a valuable tool to assess disease severity and treatment efficacy in AD mouse models.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] The selective BACE1 inhibitor VIa reduces Aβ production and ameliorates behavioral deficits in a mouse model of Alzheimer's disease
    Cheng, Xiao-rui
    Zhou, Yu
    Gu, Wei
    Nie, Ai-hua
    Cheng, Jun-ping
    Zhou, Jin-wu
    Zhou, Wen-xia
    Zhang, Yong-xiang
    ACTA PHARMACOLOGICA SINICA, 2013, 34 : 102 - 102
  • [22] Evaluation of the protective role of melatonin on the behavioral effects of aluminum in a mouse model of Alzheimer's disease
    Garcia, Tania
    Ribes, Diana
    Teresa Colomina, Maria
    Cabre, Maria
    Domingo, Jose L.
    Gomez, Mercedes
    TOXICOLOGY, 2009, 265 (1-2) : 49 - 55
  • [23] The IDO Inhibitor Coptisine Ameliorates Cognitive Impairment in a Mouse Model of Alzheimer's Disease
    Yu, Dan
    Tao, Bang-Bao
    Yang, Yun-Yun
    Du, Li-Sha
    Yang, Shuang-Shuang
    He, Xiao-Jie
    Zhu, Yu-Wen
    Yan, Jun-Kai
    Yang, Qing
    JOURNAL OF ALZHEIMERS DISEASE, 2015, 43 (01) : 291 - 302
  • [24] Behavioral and Neurochemical Alterations Induced by vanillin in a Mouse Model of Alzheimer's disease
    Abuhamdah, Sawsan
    Thalji, Duaa
    Abuirmeileh, Naji
    Bahnassi, Anas
    Salahat, Izzedin
    Abuirmeileh, Amjad
    INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2017, 13 (06) : 573 - 582
  • [25] Cortical cerebrovascular and metabolic perturbations in the 5xFAD mouse model of Alzheimer's disease
    Jullienne, Amandine
    Szu, Jenny I. I.
    Quan, Ryan
    Trinh, Michelle V. V.
    Norouzi, Tannoz
    Noarbe, Brenda P. P.
    Bedwell, Amanda A. A.
    Eldridge, Kierra
    Persohn, Scott C. C.
    Territo, Paul R. R.
    Obenaus, Andre
    FRONTIERS IN AGING NEUROSCIENCE, 2023, 15
  • [26] Altered Expression of Small Intestinal Drug Transporters and Hepatic Metabolic Enzymes in a Mouse Model of Familial Alzheimer's Disease
    Pan, Yijun
    Omori, Kotaro
    Ali, Izna
    Tachikawa, Masanori
    Terasaki, Tetsuya
    Brouwer, Kim L. R.
    Nicolazzo, Joseph A.
    MOLECULAR PHARMACEUTICS, 2018, 15 (09) : 4073 - 4083
  • [27] Suppression of glymphatic fluid transport in a mouse model of Alzheimer's disease
    Peng, Weiguo
    Achariyar, Thiyagarajan M.
    Li, Baoman
    Liao, Yonghong
    Mestre, Humberto
    Hitomi, Emi
    Regan, Sean
    Kasper, Tristan
    Peng, Sisi
    Ding, Fengfei
    Benveniste, Helene
    Nedergaard, Maiken
    Deane, Rashid
    NEUROBIOLOGY OF DISEASE, 2016, 93 : 215 - 225
  • [28] Ketogenic diet ameliorates cognitive impairment and neuroinflammation in a mouse model of Alzheimer's disease
    Xu, Yunlong
    Jiang, Chenyu
    Wu, Junyan
    Liu, Peidong
    Deng, Xiaofei
    Zhang, Yadong
    Peng, Bo
    Zhu, Yingjie
    CNS NEUROSCIENCE & THERAPEUTICS, 2022, 28 (04) : 580 - 592
  • [29] Oleic Acid Ameliorates Amyloidosis in Cellular and Mouse Models of Alzheimer's Disease
    Amtul, Zareen
    Westaway, David
    Cechetto, David F.
    Rozmahel, Richard F.
    BRAIN PATHOLOGY, 2011, 21 (03) : 321 - 329
  • [30] A Noncompetitive BACE1 Inhibitor TAK-070 Ameliorates Aβ Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease
    Fukumoto, Hiroaki
    Takahashi, Hideki
    Tarui, Naoki
    Matsui, Junji
    Tomita, Taisuke
    Hirode, Mitsuhiro
    Sagayama, Masumi
    Maeda, Ryouta
    Kawamoto, Makiko
    Hirai, Kazuko
    Terauchi, Jun
    Sakura, Yasufumi
    Kakihana, Mitsuru
    Kato, Kaneyoshi
    Iwatsubo, Takeshi
    Miyamoto, Masaomi
    JOURNAL OF NEUROSCIENCE, 2010, 30 (33) : 11157 - 11166